Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
Drug Resistance, Neoplasm
The majority of patients with advanced lung adenocarcinomas harboring EGFR exon20ins do not respond to EGFR TKI therapy. Standard chemotherapy should be used as first-line therapy. These patients have an OS similar to that of patients with sensitizing EGFR mutations. Individuals with certain variants such as FQEA and ASV may respond to erlotinib. Cancer 2015;121:3212-3220. © 2015 American Cancer Society.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency